Verrica Pharmaceuticals (VRCA) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Verrica Pharmaceuticals in October 2026.
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
Verrica Pharmaceuticals (VRCA) Stock Forecast
Analyst price target, next 12 months
$13.89
+217.1% vs today's $4.38
Price range over the last 12 months
Close to its 12-month low
Analysts covering Verrica Pharmaceuticals have a consensus 12-month target of $13.89, above the current price of $4.38.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 18 Sep 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Verrica Pharmaceuticals' stock with a target price of $13.89, indicating strong potential growth.
Financial Health
Verrica Pharmaceuticals is generating strong revenue and cash flow, showcasing good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
